2026/2027 CMDT Master’s Blueprint: The
Elite Test Bank
PART I: THE PRIMER
Mastering the 2026/2027 regulatory redlines separates protocol-driven technicians from
autonomous diagnostic clinicians. This gauntlet replaces academic memorization with the
razor-sharp clinical intuition required to avert catastrophic patient outcomes.
● Sepsis 2025: Shock = 1-hour STAT bundle; Stable = 3-hour Assess-and-Treat.
● GOLD 2026: Group E = \ge 1 moderate exacerbation; Eosinophils \ge 300 = Dupilumab.
● AHA 2025: Post-ROSC MAP \ge 65 mmHg; avoid head-up CPR.
● ADA 2026: Pregnancy HTN threshold = 140/90; GLP-1s indicated for T1D obesity.
● TJC NPG 12: Staffing inadequacy is a sentinel accreditation failure.
Domain 2026/2027 Regulatory Redline Clinical Implication
Cardiovascular (AHA) PREVENT score \ge 7.5\% Replaces PCE; initiates Stage
1 HTN pharmacotherapy.
Sepsis (SSC) Abolition of universal 30 mL/kg Precision dynamic fluid
assessment required for
CHF/ESRD.
Kidney (KDIGO) G3a A2 "Red Zone" Albuminuria independently
multiplies cardiovascular
mortality.
Gastrointestinal (ACG) Optimized BQT 14-day Bismuth quadruple therapy is
mandate first-line; doxycycline
substitution banned.
PART II: THE ELITE TEST BANK
Q1: A patient presents with suspected infection, a lactate of 1.8 mmol/L, and a MAP of 72
mmHg. What is the immediate regulatory timeline for antimicrobial administration under
the 2025 Surviving Sepsis guidelines? A) 1-hour STAT bundle execution. B) 3-hour
assess-and-treat window. C) Withhold antimicrobials until blood cultures result. D) Immediate 30
mL/kg normal saline bolus.
● The Answer: B (3-hour assess-and-treat window).
● Distractor Analysis: Option A is the obsolete Sepsis-3 trap; rushing broad-spectrum
antibiotics in hemodynamically stable patients breeds resistance. Option C delays care
lethally if the patient decompensates. Option D is contraindicated; normal saline causes
hyperchloremic acidosis, and fluids are not mandated without hypoperfusion.
● The Mentor's Analysis: The 2025 redline eliminates the universal 1-hour bundle. If the
patient lacks shock criteria (MAP \ge 65, Lactate < 4), you operate within the 3-hour
"investigate, then treat" window. This protects the patient from nephrotoxic empiric
antibiotics while allowing time for precise diagnostics like urinalysis or imaging.
Q2: Under the GOLD 2026 report, what clinical event instantly reclassifies a
treatment-naïve COPD patient into the high-risk "Group E" category? A) FEV_1/FVC <
0.70. B) A single moderate or severe exacerbation. C) Blood eosinophil count > 300 cells/µL. D)
,Daily reliance on a short-acting bronchodilator.
● The Answer: B (A single moderate or severe exacerbation).
● Distractor Analysis: Option A is the diagnostic floor for COPD, not a grouping metric.
Option C is the threshold for biologic initiation (Dupilumab), not Group E classification.
Option D indicates poor symptom control but does not define the exacerbation-prone
group.
● The Mentor's Analysis: GOLD 2026 radically lowered the threshold for treatment
escalation. A single moderate exacerbation (requiring oral corticosteroids or antibiotics)
prior to maintenance therapy proves the patient is biologically unstable and requires
immediate dual therapy (LABA + LAMA) to prevent major acute cardiac events.
Q3: The 2025 AHA/ACC Hypertension Guidelines mandate the initiation of BP-lowering
medication for Stage 1 Hypertension (130-139/80-89 mmHg) when the 10-year PREVENT
total CVD risk score reaches what threshold? A) \ge 5.0\% B) \ge 7.5\% C) \ge 10.0\% D) \ge
15.0\%
● The Answer: B (\ge 7.5\%).
● Distractor Analysis: Option A is sub-clinical for intervention. Option C is the outdated
Pooled Cohort Equation (PCE) threshold. Option D is the Framingham risk equivalent
used in SPRINT, but not the PREVENT metric.
● The Mentor's Analysis: The 2025 guidelines retired the PCE in favor of the PREVENT
equation, which estimates total CVD risk (including heart failure) over 10 years. A score of
\ge 7.5\% in a patient with Stage 1 HTN demands immediate pharmacological intervention
if 3-6 months of lifestyle modification fails.
Q4: A treatment-naïve patient is diagnosed with H. pylori. Penicillin allergy status is
unknown. What is the 2024 ACG preferred first-line eradication protocol? A) 14-day
Clarithromycin Triple Therapy. B) 10-day Concomitant Therapy. C) 14-day Optimized Bismuth
Quadruple Therapy. D) 14-day Levofloxacin Triple Therapy.
● The Answer: C (14-day Optimized Bismuth Quadruple Therapy).
● Distractor Analysis: Option A was removed as first-line due to rising macrolide
resistance. Option B is no longer recommended. Option D is reserved strictly as a salvage
therapy when susceptibility is known.
● The Mentor's Analysis: Optimized Bismuth Quadruple Therapy (BQT) consists of a PPI,
bismuth, metronidazole, and tetracycline for exactly 14 days. The "optimization" mandate
strictly prohibits substituting doxycycline for tetracycline, which drops eradication rates by
up to 17%.
Q5: According to the 2026 ADA protocol, what is the prerequisite for initiating
Continuous Glucose Monitoring (CGM) in a newly diagnosed Type 2 Diabetic starting
basal insulin? A) 6 months of uncontrolled HbA1c. B) No prerequisite; recommended at the
onset of insulin therapy. C) Documented severe hypoglycemic events requiring EMS. D) Prior
authorization demonstrating failure of two oral agents.
● The Answer: B (No prerequisite; recommended at the onset of insulin therapy).
● Distractor Analysis: Options A, C, and D represent obsolete, cost-gatekeeping
mentalities. The ADA explicitly removed prior treatment prerequisites for CGM and
Automated Insulin Delivery (AID) systems.
● The Mentor's Analysis: The 2026 "Tech-First" protocol establishes CGM as
foundational, not supplementary. It is recommended at diabetes onset for anyone on
insulin or sulfonylureas to optimize time-in-range (TIR) and avert silent hypoglycemic
neurologic damage.
Q6: According to the Joint Commission’s 2026 National Performance Goal (NPG) 12,
, what is the regulatory consequence of inadequate nurse staffing? A) An internal
performance improvement plan. B) A financial penalty assessed by CMS. C) A direct threat to
hospital accreditation and deemed status. D) Reassignment of the Chief Medical Officer.
● The Answer: C (A direct threat to hospital accreditation and deemed status).
● Distractor Analysis: Option A is a basic management tool, not the regulatory
consequence. Option B is a downstream CMS effect, but TJC controls accreditation.
Option D deflects accountability; NPG 12 explicitly holds the Nurse Executive
accountable.
● The Mentor's Analysis: Staffing is no longer a budget variance; it is a sentinel safety
metric. NPG 12.02.01 requires 24/7 RN coverage and explicitly links staffing adequacy to
patient safety outcomes. Failure to comply jeopardizes Medicare/Medicaid participation
conditions.
Q7: Under the 2025 KDIGO guidelines, a patient with an eGFR of 52 mL/min/1.73m² and
an Albumin-to-Creatinine Ratio (ACR) of 150 mg/g is classified into which clinical risk
zone? A) G2 A1 (Green Zone). B) G3a A2 (Red Zone). C) G3b A3 (Orange Zone). D) G4 A2
(Yellow Zone).
● The Answer: B (G3a A2 (Red Zone)).
● Distractor Analysis: Option A represents mild disease. Option C overestimates the GFR
drop. Option D indicates severe GFR loss. G3a (45-59) + A2 (30-300) defines the specific
intersection.
● The Mentor's Analysis: The 2025 KDIGO update emphasizes the "CGA" (Cause, GFR,
Albuminuria) classification. The G3a A2 intersection is a critical "Red Zone" marking the
inflection point where cardiovascular mortality risk exponentially accelerates
independently of renal failure.
Q8: Under the 2025 AHA guidelines, what is the strict target for glucose management in
an adult patient who has achieved Return of Spontaneous Circulation (ROSC)? A) 40 - 80
mg/dL. B) 70 - 180 mg/dL. C) 150 - 250 mg/dL. D) < 110 mg/dL.
● The Answer: B (70 - 180 mg/dL).
● Distractor Analysis: Option A ensures lethal neuro-hypoglycemia. Option C permits
cytotoxic hyperglycemia. Option D is the obsolete "tight control" parameter that increased
mortality in ICU trials.
● The Mentor's Analysis: Post-arrest brains are exceptionally vulnerable to metabolic
extremes. The 2025 AHA mandate is simple: avoid both hypoglycemia (< 70) and
hyperglycemia (> 180) to preserve the ischemic penumbra during targeted temperature
management.
Q9: An adult patient achieves ROSC after 15 minutes of CPR. He is unresponsive to
verbal commands. The 2025 AHA guidelines recommend targeted temperature
management (TTM). What is the mandated duration for this intervention? A) At least 12
hours. B) At least 24 hours. C) At least 36 hours. D) At least 72 hours.
● The Answer: C (At least 36 hours).
● Distractor Analysis: Option B (24 hours) is the outdated historical standard. Option D
extends cooling beyond therapeutic benefit, risking severe coagulopathy and
immunosuppression.
● The Mentor's Analysis: The 2025 update explicitly extended the duration of temperature
control (whether hypothermic at 32-34°C or normothermic fever-prevention at 36-37.5°C)
to at least 36 hours to aggressively combat the secondary phase of anoxic brain injury
and reperfusion inflammation.
Q10: The 2022 CDC Opioid Prescribing Guidelines (featured in CMDT 2024) drastically
Elite Test Bank
PART I: THE PRIMER
Mastering the 2026/2027 regulatory redlines separates protocol-driven technicians from
autonomous diagnostic clinicians. This gauntlet replaces academic memorization with the
razor-sharp clinical intuition required to avert catastrophic patient outcomes.
● Sepsis 2025: Shock = 1-hour STAT bundle; Stable = 3-hour Assess-and-Treat.
● GOLD 2026: Group E = \ge 1 moderate exacerbation; Eosinophils \ge 300 = Dupilumab.
● AHA 2025: Post-ROSC MAP \ge 65 mmHg; avoid head-up CPR.
● ADA 2026: Pregnancy HTN threshold = 140/90; GLP-1s indicated for T1D obesity.
● TJC NPG 12: Staffing inadequacy is a sentinel accreditation failure.
Domain 2026/2027 Regulatory Redline Clinical Implication
Cardiovascular (AHA) PREVENT score \ge 7.5\% Replaces PCE; initiates Stage
1 HTN pharmacotherapy.
Sepsis (SSC) Abolition of universal 30 mL/kg Precision dynamic fluid
assessment required for
CHF/ESRD.
Kidney (KDIGO) G3a A2 "Red Zone" Albuminuria independently
multiplies cardiovascular
mortality.
Gastrointestinal (ACG) Optimized BQT 14-day Bismuth quadruple therapy is
mandate first-line; doxycycline
substitution banned.
PART II: THE ELITE TEST BANK
Q1: A patient presents with suspected infection, a lactate of 1.8 mmol/L, and a MAP of 72
mmHg. What is the immediate regulatory timeline for antimicrobial administration under
the 2025 Surviving Sepsis guidelines? A) 1-hour STAT bundle execution. B) 3-hour
assess-and-treat window. C) Withhold antimicrobials until blood cultures result. D) Immediate 30
mL/kg normal saline bolus.
● The Answer: B (3-hour assess-and-treat window).
● Distractor Analysis: Option A is the obsolete Sepsis-3 trap; rushing broad-spectrum
antibiotics in hemodynamically stable patients breeds resistance. Option C delays care
lethally if the patient decompensates. Option D is contraindicated; normal saline causes
hyperchloremic acidosis, and fluids are not mandated without hypoperfusion.
● The Mentor's Analysis: The 2025 redline eliminates the universal 1-hour bundle. If the
patient lacks shock criteria (MAP \ge 65, Lactate < 4), you operate within the 3-hour
"investigate, then treat" window. This protects the patient from nephrotoxic empiric
antibiotics while allowing time for precise diagnostics like urinalysis or imaging.
Q2: Under the GOLD 2026 report, what clinical event instantly reclassifies a
treatment-naïve COPD patient into the high-risk "Group E" category? A) FEV_1/FVC <
0.70. B) A single moderate or severe exacerbation. C) Blood eosinophil count > 300 cells/µL. D)
,Daily reliance on a short-acting bronchodilator.
● The Answer: B (A single moderate or severe exacerbation).
● Distractor Analysis: Option A is the diagnostic floor for COPD, not a grouping metric.
Option C is the threshold for biologic initiation (Dupilumab), not Group E classification.
Option D indicates poor symptom control but does not define the exacerbation-prone
group.
● The Mentor's Analysis: GOLD 2026 radically lowered the threshold for treatment
escalation. A single moderate exacerbation (requiring oral corticosteroids or antibiotics)
prior to maintenance therapy proves the patient is biologically unstable and requires
immediate dual therapy (LABA + LAMA) to prevent major acute cardiac events.
Q3: The 2025 AHA/ACC Hypertension Guidelines mandate the initiation of BP-lowering
medication for Stage 1 Hypertension (130-139/80-89 mmHg) when the 10-year PREVENT
total CVD risk score reaches what threshold? A) \ge 5.0\% B) \ge 7.5\% C) \ge 10.0\% D) \ge
15.0\%
● The Answer: B (\ge 7.5\%).
● Distractor Analysis: Option A is sub-clinical for intervention. Option C is the outdated
Pooled Cohort Equation (PCE) threshold. Option D is the Framingham risk equivalent
used in SPRINT, but not the PREVENT metric.
● The Mentor's Analysis: The 2025 guidelines retired the PCE in favor of the PREVENT
equation, which estimates total CVD risk (including heart failure) over 10 years. A score of
\ge 7.5\% in a patient with Stage 1 HTN demands immediate pharmacological intervention
if 3-6 months of lifestyle modification fails.
Q4: A treatment-naïve patient is diagnosed with H. pylori. Penicillin allergy status is
unknown. What is the 2024 ACG preferred first-line eradication protocol? A) 14-day
Clarithromycin Triple Therapy. B) 10-day Concomitant Therapy. C) 14-day Optimized Bismuth
Quadruple Therapy. D) 14-day Levofloxacin Triple Therapy.
● The Answer: C (14-day Optimized Bismuth Quadruple Therapy).
● Distractor Analysis: Option A was removed as first-line due to rising macrolide
resistance. Option B is no longer recommended. Option D is reserved strictly as a salvage
therapy when susceptibility is known.
● The Mentor's Analysis: Optimized Bismuth Quadruple Therapy (BQT) consists of a PPI,
bismuth, metronidazole, and tetracycline for exactly 14 days. The "optimization" mandate
strictly prohibits substituting doxycycline for tetracycline, which drops eradication rates by
up to 17%.
Q5: According to the 2026 ADA protocol, what is the prerequisite for initiating
Continuous Glucose Monitoring (CGM) in a newly diagnosed Type 2 Diabetic starting
basal insulin? A) 6 months of uncontrolled HbA1c. B) No prerequisite; recommended at the
onset of insulin therapy. C) Documented severe hypoglycemic events requiring EMS. D) Prior
authorization demonstrating failure of two oral agents.
● The Answer: B (No prerequisite; recommended at the onset of insulin therapy).
● Distractor Analysis: Options A, C, and D represent obsolete, cost-gatekeeping
mentalities. The ADA explicitly removed prior treatment prerequisites for CGM and
Automated Insulin Delivery (AID) systems.
● The Mentor's Analysis: The 2026 "Tech-First" protocol establishes CGM as
foundational, not supplementary. It is recommended at diabetes onset for anyone on
insulin or sulfonylureas to optimize time-in-range (TIR) and avert silent hypoglycemic
neurologic damage.
Q6: According to the Joint Commission’s 2026 National Performance Goal (NPG) 12,
, what is the regulatory consequence of inadequate nurse staffing? A) An internal
performance improvement plan. B) A financial penalty assessed by CMS. C) A direct threat to
hospital accreditation and deemed status. D) Reassignment of the Chief Medical Officer.
● The Answer: C (A direct threat to hospital accreditation and deemed status).
● Distractor Analysis: Option A is a basic management tool, not the regulatory
consequence. Option B is a downstream CMS effect, but TJC controls accreditation.
Option D deflects accountability; NPG 12 explicitly holds the Nurse Executive
accountable.
● The Mentor's Analysis: Staffing is no longer a budget variance; it is a sentinel safety
metric. NPG 12.02.01 requires 24/7 RN coverage and explicitly links staffing adequacy to
patient safety outcomes. Failure to comply jeopardizes Medicare/Medicaid participation
conditions.
Q7: Under the 2025 KDIGO guidelines, a patient with an eGFR of 52 mL/min/1.73m² and
an Albumin-to-Creatinine Ratio (ACR) of 150 mg/g is classified into which clinical risk
zone? A) G2 A1 (Green Zone). B) G3a A2 (Red Zone). C) G3b A3 (Orange Zone). D) G4 A2
(Yellow Zone).
● The Answer: B (G3a A2 (Red Zone)).
● Distractor Analysis: Option A represents mild disease. Option C overestimates the GFR
drop. Option D indicates severe GFR loss. G3a (45-59) + A2 (30-300) defines the specific
intersection.
● The Mentor's Analysis: The 2025 KDIGO update emphasizes the "CGA" (Cause, GFR,
Albuminuria) classification. The G3a A2 intersection is a critical "Red Zone" marking the
inflection point where cardiovascular mortality risk exponentially accelerates
independently of renal failure.
Q8: Under the 2025 AHA guidelines, what is the strict target for glucose management in
an adult patient who has achieved Return of Spontaneous Circulation (ROSC)? A) 40 - 80
mg/dL. B) 70 - 180 mg/dL. C) 150 - 250 mg/dL. D) < 110 mg/dL.
● The Answer: B (70 - 180 mg/dL).
● Distractor Analysis: Option A ensures lethal neuro-hypoglycemia. Option C permits
cytotoxic hyperglycemia. Option D is the obsolete "tight control" parameter that increased
mortality in ICU trials.
● The Mentor's Analysis: Post-arrest brains are exceptionally vulnerable to metabolic
extremes. The 2025 AHA mandate is simple: avoid both hypoglycemia (< 70) and
hyperglycemia (> 180) to preserve the ischemic penumbra during targeted temperature
management.
Q9: An adult patient achieves ROSC after 15 minutes of CPR. He is unresponsive to
verbal commands. The 2025 AHA guidelines recommend targeted temperature
management (TTM). What is the mandated duration for this intervention? A) At least 12
hours. B) At least 24 hours. C) At least 36 hours. D) At least 72 hours.
● The Answer: C (At least 36 hours).
● Distractor Analysis: Option B (24 hours) is the outdated historical standard. Option D
extends cooling beyond therapeutic benefit, risking severe coagulopathy and
immunosuppression.
● The Mentor's Analysis: The 2025 update explicitly extended the duration of temperature
control (whether hypothermic at 32-34°C or normothermic fever-prevention at 36-37.5°C)
to at least 36 hours to aggressively combat the secondary phase of anoxic brain injury
and reperfusion inflammation.
Q10: The 2022 CDC Opioid Prescribing Guidelines (featured in CMDT 2024) drastically
